Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGDS | O60760 | 1/20 | 0.52 |
| ▸ | MAOA | P21397 | 6/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | AR | P10275 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | QPCT | Q16769 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | PIM1 | P11309 | 1/20 | 0.38 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.38 |
| ▸ | BAZ2A | Q9UIF9 | 1/20 | 0.38 |
| ▸ | EGFR | P00533 | 1/20 | 0.38 |
| ▸ | KDR | P35968 | 1/20 | 0.38 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4265897 | 0.99 | HPGDS (0.53) | HPGDSMAOAMAOBSMN1; SMN2RAB9A | |
| SCHEMBL2978210 | 0.81 | MAOA (0.42) | MAOASMN1; SMN2RAB9AARTP53 | |
| Bromide SCHEMBL2979882 | 0.80 | HPGDS (0.57) | HPGDSMAOAMAOBSMN1; SMN2RAB9A | |
| Bromide SCHEMBL2983628 | 0.80 | HPGDS (0.57) | HPGDSMAOAMAOBSMN1; SMN2RAB9A | |
| Bromide SCHEMBL2984301 | 0.80 | HPGDS (0.60) | HPGDSSMN1; SMN2RAB9AARL3MBTL1 | |
| Bromide SCHEMBL2973216 | 0.80 | HPGDS (0.76) | HPGDSSMN1; SMN2RAB9AL3MBTL1NPC1 | |
| SCHEMBL4262100 | 0.79 | HPGDS (0.59) | HPGDSMAOAMAOBSMN1; SMN2RAB9A | |
| SCHEMBL3772350 | 0.79 | HPGDS (0.59) | HPGDSMAOAMAOBSMN1; SMN2RAB9A | |
| SCHEMBL4259512 | 0.79 | HPGDS (0.59) | HPGDSMAOAMAOBSMN1; SMN2RAB9A | |
| SCHEMBL2297392 | 0.78 | HPGDS (0.78) | HPGDSSMN1; SMN2RAB9AARTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7786143-B2 | Thiazolyl piperidine derivatives | HOFFMAN-LA ROCHE INC. (US) | 2010-08-31 | — | — | US | disclosed |
| EP-1945635-B1 | THIAZOLYL PIPERIDINE DERIVATIVES USEFUL AS H3 RECEPTOR MODULATORS | HOFFMANN LA ROCHE (CH) | 2009-05-06 | — | — | EP | disclosed |
| EP-1945635-A2 | THIAZOLYL PIPERIDINE DERIVATIVES USEFUL AS H3 RECEPTOR MODULATORS | F.HOFFMANN-LA ROCHE AG (CH) | 2008-07-23 | — | — | EP | disclosed |
| WO-2007020213-A2 | THIAZOLYL PIPERIDINE DERIVATIVES USEFUL AS H3 RECEPTOR MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-02-22 | — | — | WO | disclosed |
| US-20070043083-A1 | Thiazolyl piperidine derivatives | HOFFMANN-LA ROCHE INC. | 2007-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043083-A1 | Thiazolyl piperidine derivatives | HRH3, HRH4, H1-3 | HPGDS 658/4885MAOA 1810/4885MAOB 1694/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.